Israel is among the growing list of countries that are almost completely getting behind the cannabis industry. It is already the leader in medical cannabis research and medical sales are common in the country. As the industry continues to expand, Israel will now count on the support of Aurora Cannabis, which has signed a supply agreement with Israel-based Cantek Holdings, a leading company in the medical cannabis ecosystem.
The new agreement, announced yesterday, will see Aurora supply Cantek with bulk flower for a period of two years, after which they entities will explore extending the agreement. Aurora has agreed to give Cantek at least 4,000kg of bulk dried flower each year, which its new partner will process and distribute as a co-branded, Aurora/Cantek brand in the Israeli market. As the industry continues to grow, the new co-branded solution could also be introduced into international markets. According to the announcement, Aurora has already sent its first shipment to Cantek, which it completed last week.
Aurora CEO Miguel Martin says of the new partnership, “We are excited about our strategic relationship with Cantek, a leader in the Israeli market. This Agreement provides Aurora with a great opportunity to expand our medical cannabis brand and industry-leading science in one of our key international markets of focus. Today’s announcement demonstrates more than just a supply agreement. It’s about the strength and quality of the Aurora medical brand being validated once again by the world’s medical cannabis markets, including countries like Israel in which we had no distribution prior to today. We consider this Agreement to be a significant step for Aurora, and we look forward to bringing our high-quality medical cannabis products to patients in Israel.”
Cantek currently has partnerships with drugstore chains, distribution companies, medical and health clinics and more in Israel. The company’s CEO, Netsah Israel, adds in the announcement, “We are proud to partner with Aurora, a global leader who shares with us the same quality values and commitments of meeting patients’ needs and improving their quality of life. This is a vote of confidence in Cantek’s leadership and the Israeli market.”